News & Events

Recent Press Releases

GeneCentric Therapeutics to Present New Analyses of Molecular Characterization and Prediction of Treatment Response in Patients with Muscle Invasive Bladder Cancer (MIBC)

New molecular analyses to be presented at ASCO Genitourinary Cancers Symposium Durham, NC, February 13, 2020 – GeneCentric Therapeutics today announced it will present two posters during the ASCO GU Cancers Symposium to be held in San Francisco, California, February 13-15, 2020.  The data are derived from GeneCentric’s expertise in the identification of RNA-based Predictive […]

GeneCentric Therapeutics Acquires Select ImmunoGenomics

Combined company uniquely suited to drive precision oncology forward with RNA technologies to identify oncology drug responder populations Durham, NC, August 15, 2019 – GeneCentric Therapeutics, Inc. today announced that it has acquired Select ImmunoGenomics, LLC, a Chapel Hill, NC-based provider of advanced immunogenomic, data analysis and biomarker development services to support the development of […]

GeneCentric and Collaborators at Washington University Advance Academic-Industry Head and Neck Cancer Partnership under NCI Grant

Partners to initiate Second Phase of R01-Awarded Research Durham, NC, August 9, 2019 – GeneCentric Therapeutics, Inc. today announced that it has entered the second phase of an academic-industry collaboration with Jose Zevallos MD, MPH, Chief of the Division of Head and Neck Oncologic Surgery in the Department of Otolaryngology at Washington University School of […]

Recent News

GeneCentric has moved its offices

GeneCentric Therapeutics is now located at 100 Capitola Dr, Suite275 Durham, NC 27713

Covid-19 Status

GeneCentric Therapeutics continues to monitor the evolving novel Coronavirus (COVID-19) situation closely. We are following the Centers for Disease Control and Prevention (CDC) recommendations on prevention and spread of the virus along with specific guidance for travelers. Currently, the company doesn’t anticipate any changes with its current client projects and will continuously update clients.

Dr. Myla Lai-Goldman discusses GeneCentric’s Cancer Subtyping Platform (CSP™) with Healtheo360’s David Duplay and Courtland Long

Dr. Myla Lai-Goldman discusses GeneCentric’s Cancer Subtyping Platform (CSP™) with Healtheo360’s David Duplay and Courtland Long

Recent Publications

Fibroblast growth factor receptor status and response to immune checkpoint inhibition in metastatic urothelial cancer.”

Title: “Fibroblast growth factor receptor status and response to immune checkpoint inhibition in metastatic urothelial cancer.” Abstract Number: 458 Date:  February 15, 2019 Presenter: Tracy L. Rose, MD, MPH, Assistant Professor, Division of Hematology/Oncology, UNC Department of Medicine, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC To read the abstract, please visit: https://meetinglibrary.asco.org/record/169672/abstract View the poster here